Quick summary

Turmeric (Curcuma longa) and its active constituent curcumin have been studied extensively for potential clinical benefits in metabolic syndrome, diabetes, rheumatoid arthritis, knee osteoarthritis, oral health, and cancer adjunctive therapy. Clinical trials and meta-analyses suggest turmeric/curcumin may improve glycemic control, lipid profiles, inflammatory biomarkers, and symptoms in conditions such as type 2 diabetes and rheumatoid arthritis. Nano-formulations and combinations with piperine enhance bioavailability and effects. Safety data from human studies indicate turmeric is generally well tolerated, with mild gastrointestinal symptoms and rare somnolence reported. However, variability in formulations, dosages, and study durations, along with some inconsistent effects and methodological limitations, call for cautious interpretation and further well-designed clinical trials to confirm therapeutic roles and safety profiles.

What is it

Turmeric is a perennial herb in the ginger family, native to South Asia and widely used as a spice and traditional medicine. Its rhizome is the source of turmeric powder, which contains curcumin, a polyphenolic compound primarily responsible for its yellow color and biological activities. Curcumin is the most studied active constituent associated with anti-inflammatory and antioxidant effects.

Traditional uses

Traditionally, turmeric has been used in Ayurvedic and Chinese medicine for centuries to address inflammatory conditions, digestive issues, wound healing, and liver disorders. It has also been applied topically for skin disorders and used as a dietary supplement to promote general health and vitality.

Active compounds

  • Curcumin: The main curcuminoid with antioxidant and anti-inflammatory properties.
  • Other curcuminoids: demethoxycurcumin, bisdemethoxycurcumin.
  • Essential oils and volatile compounds contributing to turmeric’s aroma and potential bioactivity.

Potential benefits with evidence levels

  • Type 2 diabetes mellitus and prediabetes: Multiple randomized controlled trials and meta-analyses indicate curcumin/turmeric supplementation may reduce fasting blood glucose, HbA1c, insulin levels, and insulin resistance, especially at doses ≥1 g/day and enhanced formulations. (Human clinical evidence, RCTs, meta-analyses)
  • Rheumatoid arthritis: Preliminary evidence from systematic reviews suggests curcumin supplementation may reduce disease activity scores, inflammatory markers (ESR, CRP), rheumatoid factor, and joint symptoms, though certainty is very low to low. (Human clinical evidence, RCTs, meta-analyses)
  • Knee osteoarthritis pain and function: Meta-analyses show modified turmeric formulations may significantly reduce pain compared to placebo, with efficacy comparable to NSAIDs, and improved joint function. (Human clinical evidence, RCTs, meta-analyses)
  • Lipid profile improvement in metabolic disorders: Turmeric, especially when combined with piperine, may reduce triglycerides, total cholesterol, LDL, and increase HDL cholesterol in adults with metabolic risk. (Human clinical evidence, RCTs, meta-analyses)
  • Oral mucositis due to cancer therapy: Curcumin formulations may reduce severity, onset, and pain of oral mucositis and support healing in patients undergoing chemotherapy or radiotherapy. (Human clinical evidence, RCTs, systematic reviews)
  • Metabolic syndrome and inflammatory markers: Curcumin may improve glycemic and lipid parameters and reduce inflammatory cytokines (CRP, TNF-α, IL-6) in metabolic syndrome, though heterogeneity is moderate to high. (Human clinical evidence, meta-analyses)
  • Wound healing: Clinical trials suggest curcumin might improve wound healing outcomes with minimal adverse events. (Human clinical evidence, clinical trials)
  • Kidney function in diabetes: Supplementation may reduce urea levels but shows no significant effect on other kidney function markers in diabetic patients. (Human clinical evidence, RCTs, meta-analyses)
  • Hypertension in prediabetes and diabetes: Curcumin might modestly reduce systolic blood pressure, particularly in individuals with baseline hypertension. (Human clinical evidence, meta-analyses)
  • Cancer adjunctive therapy (colorectal, breast): Preliminary and limited evidence suggests possible anti-inflammatory and quality of life improvements when used adjunctively, though bioavailability and study variability limit conclusions. (Limited human clinical evidence, preliminary trials, systematic reviews)

Side effects

  • Mild and transient gastrointestinal symptoms such as nausea and diarrhea
  • Somnolence in rare cases
  • Rare hepatotoxicity reports, mostly linked to adulterated or high-dose products
  • Potential for excessive sedation and serotonin syndrome if combined with certain drugs

Drug interactions

Turmeric and curcumin may modulate cytochrome P450 enzymes, potentially affecting the metabolism of various medications. There is a potential increased risk of bleeding with concurrent use of antithrombotic or antiplatelet agents. Use with serotonergic drugs may increase the risk of serotonin syndrome. Clinical data on specific interactions remain limited, so caution and medical monitoring are advised, especially when used with chemotherapy, immunosuppressants, anticoagulants, or antiplatelets.

Who should avoid it

  • Individuals on anticoagulant or antiplatelet therapy due to bleeding risk
  • Those with known hypersensitivity to turmeric or curcumin, especially avoiding high doses or concentrated extracts
  • Patients with severe hepatic or renal impairment should use cautiously due to limited safety data
  • Pregnant and breastfeeding women, unless supervised by a healthcare practitioner, due to insufficient safety evidence
  • Avoid adulterated or poor-quality turmeric supplements to reduce risk of toxicity

Evidence limitations

  • Significant heterogeneity in study designs, dosages, formulations, and treatment durations
  • Moderate-to-high statistical heterogeneity reported in many meta-analyses
  • Small sample sizes and short duration in some clinical trials limit generalizability
  • Quality control and standardization issues with turmeric supplements impact reproducibility
  • Poor oral bioavailability of curcumin limits translation of preclinical findings to clinical effects
  • Limited long-term safety and efficacy data, especially for high-dose or novel formulations
  • Inconsistent adverse event reporting and underreporting of herb-drug interactions
  • Predominance of studies from limited geographic regions; need for more diverse populations
  • Lack of large-scale, multicenter, placebo-controlled randomized trials for many indications

References

Last reviewed

June 2024

Disclaimer: This page is for informational purposes only and is not intended to provide medical advice. Consult a healthcare professional before starting any new supplement, especially if you have existing health conditions or are taking medications.